News Hub

Real-time financial, economic, and global news with market-focused context and analysis.

Coverage spans equities, macroeconomic data, commodities, currencies, technology, politics, and global events—paired with analysis that highlights why each development matters for traders and investors. From breaking headlines to hourly market snapshots and in-depth articles, the News Hub is designed to help you stay informed, oriented, and ahead of market-moving events.

  • AppLovin downgraded; analyst opened a tactical mid-term short, implying near-term downside pressure.
  • Investor tripled IREN position after the crash, initiating a high-risk mid-term swing to capture AI cloud revenue acceleration.
  • Clarivate shows returning contract momentum and free cash flow, prompting a speculative long with defined entry and target.
  • Micron labeled oversold and recommended as a mid-term long to play AI- and data-center-driven demand recovery.
  • Traders favor selective risk-on trades in AI/cloud and semiconductors while targeting idiosyncratic shorts on valuation or legal risk.

Latest Articles

Liberty Defense Expands U.S. Distribution Footprint with New Agreement with VMI Security for HEXWAVE™

Liberty Defense Expands U.S. Distribution Footprint with New Agreement with VMI Security for HEXWAVE™

Liberty Defense Holdings Ltd. has entered a non-exclusive distribution agreement with VMI Security to expand the U.S. sales of its HEXWAVE walk-through security screening system. This partnership will leverage VMI's established customer base and sales infrastructure to accelerate adoption of Liberty's AI-powered detection technology across key secu…

Cloudastructure Management Discusses Enterprise Growth Strategy at Water Tower Research Insights Conference

Cloudastructure Management Discusses Enterprise Growth Strategy at Water Tower Research Insights Conference

Cloudastructure's management presented their growth strategy at the Water Tower Research Insights Conference, focusing on expanding deployments with major U.S. multifamily property managers, entering new vertical markets such as construction and logistics, and enhancing recurring subscription revenue. The company aims to scale commercial operations…

Polar Power CEO Arthur Sams Converts $614,700 of Debt Into Preferred Equity, Strengthening Balance Sheet

Polar Power CEO Arthur Sams Converts $614,700 of Debt Into Preferred Equity, Strengthening Balance Sheet

Polar Power's CEO Arthur Sams converted $614,700 of debt owed by the company into Series A Convertible Preferred shares, improving the company's balance sheet and shareholder equity. This move supports the company's efforts to regain compliance with Nasdaq listing requirements and signals confidence in future growth across multiple sectors includin…

HCW Biologics Announces Pricing of $1.5 Million Private Placement

HCW Biologics Announces Pricing of $1.5 Million Private Placement

HCW Biologics Inc., a clinical-stage biopharmaceutical company, announced the pricing of a $1.5 million private placement with an existing stockholder. The financing involves the issuance of pre-funded warrants and common stock purchase warrants subject to stockholder approval. Proceeds will support ongoing clinical trials of HCW9302 and advance st…

SeaStar Medical Congratulates H. David Humes, M.D., on Receiving the University of Michigan 2026 Distinguished University Innovator of the Year for Development of the SCD Therapy

SeaStar Medical Congratulates H. David Humes, M.D., on Receiving the University of Michigan 2026 Distinguished University Innovator of the Year for Development of the SCD Therapy

SeaStar Medical celebrated Dr. H. David Humes’ receipt of the University of Michigan's Distinguished University Innovator of the Year award for developing the Selective Cytopheretic Device (SCD) therapy. The therapy, commercialized as QUELIMMUNE, is FDA-approved for critically ill pediatric patients with acute kidney injury and sepsis, showing sign…

IMUNON Makes the Frontline Case for Phase 3 IMNN-001 Study: 14.7-Month OS Signal, Historical IL-12 Safety Barriers Overcome, Enrolling Ahead of Plan

IMUNON Makes the Frontline Case for Phase 3 IMNN-001 Study: 14.7-Month OS Signal, Historical IL-12 Safety Barriers Overcome, Enrolling Ahead of Plan

IMUNON, Inc. presented encouraging results from its Phase 2 OVATION 2 study of IMNN-001, demonstrating a 14.7-month median overall survival improvement in advanced ovarian cancer patients. The company highlighted the favorable safety profile of its IL-12 DNA plasmid immunotherapy and announced strong enrollment progress in the ongoing Phase 3 OVATI…

Tencent at a Discount - Position for an AI and Cloud Re-rate

Tencent at a Discount - Position for an AI and Cloud Re-rate

Tencent (TCEHY) is trading near $55.92 with a market cap of roughly $508.5B and a P/E of 15.5. AI-driven spending across games, cloud and fintech + a large payments footprint create a material re-rating opportunity. I lay out an actionable long: entry $55.50, stop $52.50, target $70.00 for a mid-term (45 trading days) trade, with clear catalysts an…

SkyAI Comments on Annual Meeting Results

SkyAI Comments on Annual Meeting Results

SkyAI, Inc. acknowledges significant shareholder concerns reflected in the 2026 Annual Meeting voting results. The Board and management are committed to thoroughly engaging with shareholders and evaluating necessary actions related to capital allocation, corporate governance, strategic direction, and shareholder communications to reduce the company…

Quantum Biopharma Licensee Unbuzzd Wellness to Advance Clinically Validated Alcohol Metabolism Accelerant After Appointing Zappy as CEO

Quantum Biopharma Licensee Unbuzzd Wellness to Advance Clinically Validated Alcohol Metabolism Accelerant After Appointing Zappy as CEO

Quantum BioPharma's licensee, Unbuzzd Wellness Inc., has appointed Michael Zapolin as CEO with plans to finance and list the company on a stock exchange as well as execute a nationwide commercial marketing and product rollout in the U.S. Unbuzzd is a clinically validated beverage that accelerates alcohol metabolism, restores mental clarity, and red…

Diginex Consolidates Group-Wide Expertise and Launches Sustainability Science & Intelligence Initiative to Accelerate Product Innovation and Drive Measurable Client Outcomes

Diginex Consolidates Group-Wide Expertise and Launches Sustainability Science & Intelligence Initiative to Accelerate Product Innovation and Drive Measurable Client Outcomes

Diginex Limited, a Nasdaq-listed RegTech company specializing in ESG and sustainability solutions, has launched a new Group-wide Subject Matter Expertise (SME) initiative. This effort consolidates the company's scientific, regulatory, and methodological expertise across its product and advisory services to drive product innovation and deliver measu…

Dillard’s Offers Exclusive Southern Living Christmas Cookbook

Dillard’s Offers Exclusive Southern Living Christmas Cookbook

Dillard's, a leading US fashion retailer, has released the Southern Living Christmas Cookbook exclusively in its stores and online as part of its 32nd annual fundraiser for Ronald McDonald House. Profits from cookbook sales will benefit select Ronald McDonald House chapters across the US, continuing Dillard's long-standing commitment to charitable …

Annexon to Present Patient Baseline Characteristics from Vonaprument Phase 3 ARCHER II Pivotal Trial for Geographic Atrophy at The Retina Society 59th Annual Scientific Meeting

Annexon to Present Patient Baseline Characteristics from Vonaprument Phase 3 ARCHER II Pivotal Trial for Geographic Atrophy at The Retina Society 59th Annual Scientific Meeting

Annexon, Inc. announced presentations highlighting patient baseline characteristics and Phase 2 vision protection findings from the ARCHER program for their investigational neuroprotective drug vonaprument in Geographic Atrophy (GA). The ongoing Phase 3 ARCHER II trial aims to replicate Phase 2 positive vision outcomes, with primary endpoint result…

ZenaTech’s ZenaDrone Advances Defense-Focused Quantum Navigation System for GPS-Denied Operations to Drone Testing Phase

ZenaTech’s ZenaDrone Advances Defense-Focused Quantum Navigation System for GPS-Denied Operations to Drone Testing Phase

ZenaTech's drone subsidiary ZenaDrone has entered the testing phase for its defense-focused quantum navigation system, designed to enable reliable drone operation in GPS-denied and satellite-compromised environments. The system aims to provide secure, redundantly layered navigation using quantum inertial sensing combined with AI path correction. In…

New Preclinical Data Further Support Potential for Tvardi’s STAT3 Inhibitors in Ulcerative Colitis (UC)

New Preclinical Data Further Support Potential for Tvardi’s STAT3 Inhibitors in Ulcerative Colitis (UC)

Tvardi Therapeutics announced new preclinical data showing that their oral STAT3 inhibitors, including next-generation TTI-109 and first-generation TTI-101, achieve high colon exposure, modulate multiple pathogenic pathways in ulcerative colitis (UC), and prevent colorectal cancer development in models. The data support advancing TTI-109 into clini…

Nuvectis Announces NXP200 Granted Breakthrough Therapy Designation in China for BRAF V600-Mutant, Recurrent or Progressive, High-Grade Glioma

Nuvectis Announces NXP200 Granted Breakthrough Therapy Designation in China for BRAF V600-Mutant, Recurrent or Progressive, High-Grade Glioma

Nuvectis Pharma announced that their drug candidate NXP200, an oral BRAF inhibitor targeting BRAF V600-mutant high-grade glioma, has been granted Breakthrough Therapy Designation by China's Center for Drug Evaluation. This designation highlights the promising clinical activity of NXP200 for patients with recurrent or progressive brain tumors. The c…

Marea Therapeutics, a Subsidiary of Lisata Therapeutics, Announces Upcoming Late-Breaking Presentation of MAR001 Clinical Data at the American Heart Association Scientific Sessions 2026

Marea Therapeutics, a Subsidiary of Lisata Therapeutics, Announces Upcoming Late-Breaking Presentation of MAR001 Clinical Data at the American Heart Association Scientific Sessions 2026

Lisata Therapeutics, through its subsidiary Marea Therapeutics, announced a late-breaking presentation of Phase 2b clinical data for MAR001, a novel monoclonal antibody targeting ANGPTL4 to treat elevated triglycerides, at the American Heart Association Scientific Sessions 2026. MAR001 aims to reduce triglycerides and improve cardiometabolic health…

Elicio Therapeutics Announces Late-Breaking Phase 2 AMPLIFY-7P Data Selected for Proffered Paper Oral Presentation at ESMO Congress 2026

Elicio Therapeutics Announces Late-Breaking Phase 2 AMPLIFY-7P Data Selected for Proffered Paper Oral Presentation at ESMO Congress 2026

Elicio Therapeutics announced that new pre-specified analyses from its Phase 2 AMPLIFY-7P study of ELI-002 7P, an immunotherapy targeting KRAS-driven pancreatic cancer, will be presented at ESMO Congress 2026. While the study did not meet its primary endpoint, the additional data provide valuable insights to refine the Phase 3 development strategy …